Edwards Lifesciences Shares Soar 3.32% On Rival's Exit

Edwards Lifesciences (EW) shares surged 3.32% intraday, reaching their highest level since July 2024, marking a three-day winning streak with a cumulative gain of 2.50%.

The strategy of buying EW shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years. The annualized return was 8.14%, slightly underperforming the market benchmark. With a final value of $2,778.66 for a $1,000 investment, the strategy showed the impact of compounded returns over 5 years, highlighting the importance of holding periods to capture long-term gains..

Edwards Lifesciences' stock experienced a notable rise due to a significant event involving its competitor, Boston Scientific. Boston Scientific announced that it would stop selling its rival heart-valve replacement systems, which led to a positive impact on Edwards Lifesciences' stock. This development highlighted the competitive advantage gained by Edwards Lifesciences as a result of Boston Scientific's exit from the market.